Financials Mithra Pharmaceuticals S.A.

Equities

MITRA

BE0974283153

Pharmaceuticals

Market Closed - Euronext Bruxelles 11:35:26 2024-04-26 am EDT 5-day change 1st Jan Change
0.216 EUR -1.82% Intraday chart for Mithra Pharmaceuticals S.A. -.--% -82.78%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 752.8 989.7 841.5 880.1 186.5 14.93 14.93 -
Enterprise Value (EV) 1 721 1,138 1,008 1,201 486.3 396.8 14.93 14.93
P/E ratio -60.6 x -37.5 x -8.76 x -7.43 x -2.79 x -0.16 x - -
Yield - - - - - - - -
Capitalization / Revenue 11.5 x 10.3 x 93.2 x 38.8 x 2.78 x 2.16 x 0.34 x 0.16 x
EV / Revenue 11 x 11.8 x 112 x 53 x 7.26 x 9.88 x 0.34 x 0.16 x
EV / EBITDA 18.8 x 35.8 x -13.7 x -15.5 x -34 x -7.52 x -0.5 x 0.44 x
EV / FCF -111 x -19.6 x -11.1 x -14 x -5.9 x -26.9 x -0.58 x 0.3 x
FCF Yield -0.9% -5.09% -9% -7.15% -17% -3.72% -174% 336%
Price to Book 4.99 x 6.29 x 5.33 x 25.6 x 5.69 x 0.44 x - -
Nbr of stocks (in thousands) 37,639 37,689 42,714 44,051 54,764 69,108 69,108 -
Reference price 2 20.00 26.26 19.70 19.98 3.405 0.2160 0.2160 0.2160
Announcement Date 3/1/19 3/9/20 3/9/21 3/8/22 3/7/23 3/8/24 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 65.46 96.5 9.03 22.67 67 40.16 43.9 95.9
EBITDA 1 38.31 31.82 -73.81 -77.45 -14.3 -52.77 -29.6 33.6
EBIT 1 35.46 34.97 -79.94 -87.88 -26.24 -139.1 - -
Operating Margin 54.16% 36.24% -885.32% -387.66% -39.17% -346.49% - -
Earnings before Tax (EBT) 1 -16.23 -40.35 -110.9 -123.8 -11.48 -161.8 - -
Net income 1 -12.36 -26.6 -92.09 -116.9 -59.62 -173.5 -55.4 13.8
Net margin -18.88% -27.56% -1,019.78% -515.59% -88.99% -432.08% -126.2% 14.39%
EPS 2 -0.3300 -0.7000 -2.250 -2.690 -1.220 -1.390 - -
Free Cash Flow 1 -6.467 -57.94 -90.67 -85.87 -82.48 -9.4 -25.9 50.1
FCF margin -9.88% -60.05% -1,004.1% -378.82% -123.11% -25.79% -59% 52.24%
FCF Conversion (EBITDA) - - - - - - - 149.11%
FCF Conversion (Net income) - - - - - - - 363.04%
Dividend per Share - - - - - - - -
Announcement Date 3/1/19 3/9/20 3/9/21 3/8/22 3/7/23 3/8/24 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q2
Net sales 1 7.035
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) -
Net income 1 -50.47
Net margin -717.4%
EPS -
Dividend per Share -
Announcement Date 9/26/23
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - 149 167 321 300 310 - -
Net Cash position 1 31.8 - - - - - - -
Leverage (Debt/EBITDA) - 4.671 x -2.256 x -4.141 x -20.96 x -5.876 x - -
Free Cash Flow 1 -6.47 -57.9 -90.7 -85.9 -82.5 -9.4 -25.9 50.1
ROE (net income / shareholders' equity) -10.4% 10.1% -43.5% -96.8% -177% -6,827% - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 4.010 4.170 3.690 0.7800 0.6000 0.4900 - -
Cash Flow per Share 2 0.0900 -1.240 -1.950 -1.710 -1.160 -0.2000 - -
Capex 1 10 11.1 10.6 11.5 25.7 9.4 9.4 9.4
Capex / Sales 15.29% 11.52% 117.88% 50.66% 38.3% 25.79% 21.41% 9.8%
Announcement Date 3/1/19 3/9/20 3/9/21 3/8/22 3/7/23 3/8/24 - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
0.216 EUR
Average target price
0.1 EUR
Spread / Average Target
-53.70%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. MITRA Stock
  4. Financials Mithra Pharmaceuticals S.A.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW